Developer docs
API playgroundTry for free, no card

Search company profiles

Fina Biosolutions

Full company profile

uuid0002u3r

Namestring
Fina Biosolutions
Legal namestring
Fina Biosolutions LLC
Websiteurl
finabio.net
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Fina Biosolutions LLC is a privately held biotechnology company founded in 2006 by Dr. Andrew Lees and headquartered in Rockville, Maryland. The company's mission is to enable affordable conjugate vaccine manufacturing for emerging markets by providing conjugation chemistry expertise, carrier proteins, laboratory services, and consulting. Its core technology is the CDAP (1-cyano-4-dimethylaminopyridine tetrafluoroborate) conjugation method and a proprietary E. coli expression system that produces CRM197 (marketed as EcoCRM) at high yields without Corynebacterium diphtheriae, reducing carrier protein costs by up to 80% versus legacy alternatives. The broader product portfolio includes tetanus toxoid variants (8MTT, rTTHc), Qβ virus-like particles, and a catalog of functionalized dextrans for research applications.

Fina Biosolutions operates four revenue streams. First, product sales of proprietary carrier proteins and bioconjugation reagents via a direct e-commerce storefront and purchase-order system, with unit prices ranging from $175 to $5,500. Second, contract laboratory services covering bioconjugation, protein expression and purification, SEC-MALS and moisture analytical services, and immunoassay design. Third, technology licensing and royalties, most notably the long-running agreement with the Serum Institute of India covering CDAP chemistry and EcoCRM, which underlies WHO-prequalified vaccines Pneumosil and MenFive, plus a non-exclusive PATH license for EcoCRM in GAVI-eligible countries. Fourth, multi-day CDAP conjugation training programs delivered by Andrew Lees and staff. The company employs 1-10 people, was bootstrapped for 18 years prior to a $3 million strategic investment by SK Bioscience in October 2024, and operates a deliberately low-margin 'not-for-much profit' model intended to expand global vaccine access rather than maximize unit economics.

Short descriptiontext

Fina Biosolutions is a Rockville, Maryland biotech that licenses proprietary CDAP conjugation chemistry and E. coli-produced CRM197 (EcoCRM) carrier proteins to enable affordable conjugate vaccine manufacturing, serving emerging market vaccine producers, global health organizations, and research institutions worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
conjugate vaccine technology, bioconjugation services, vaccine carrier proteins, protein expression services, conjugation chemistry
Industry1 code
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Conjugate Vaccine Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales (Carrier Proteins & Reagents)
TypeOne Time License
Description

Sale of proprietary vaccine carrier proteins (EcoCRM, rTTHc, 8MTT), functionalized dextrans, specialty immunoreagents, and related bioconjugation reagents to vaccine manufacturers and research institutions. Products sold via online storefront and purchase orders.

finabio.net
2Laboratory & Consulting Services
TypeProfessional Services
Description

Provides bioconjugation laboratory services, protein expression and purification, analytical services (SEC-MALS, moisture analysis), and consulting to biotech and vaccine companies. Includes contract conjugation work for companies worldwide.

finabio.net
3Technology Licensing & Royalties
TypeLicensing Royalties
Description

Licenses CDAP conjugation chemistry and EcoCRM production technology to vaccine manufacturers. Receives milestone payments and royalties on vaccine sales incorporating FinaBio technology (e.g., Serum Institute of India's Pneumosil and MenFive).

finabio.net
4CDAP Training Programs
TypeProfessional Services
Description

Multi-day training programs on CDAP conjugation chemistry, delivered by Andrew Lees and FinaBio staff, covering theoretical and hands-on laboratory training, DOE-based optimization, and SEC MALS analysis.

finabio.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details7 tiers
1EcoCRM (CRM197) carrier protein
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$250 for smallest quantity through $5,000 for largest quantity. Price varies by order size; contact sales for bulk pricing.

finabio.net
2Amino Dextrans
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$175 (smallest size) through $1,150 (largest size) per unit.

finabio.net
38MTT (Tetanus Toxoid)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$275 (smallest size) through $5,500 (largest size) per unit.

finabio.net
4rTTHc carrier protein
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Available in multiple sizes; pricing available upon contact (sales@finabio.com).

finabio.net
5Anti-IgD/IgM Dextran Conjugates
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$375 (10µg) through $3,750 (500µg) per unit.

finabio.net
6Qβ VLP
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$325 (smallest size) through $975 (largest size) per unit.

finabio.net
7Specialty Immunoreagents (TNP, DNP, NP, etc.)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices range from $175 for 10mg sizes to $625 for 50mg sizes depending on product type and conjugate.

finabio.net
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1EcoCRM
Description

Economical CRM197 carrier protein produced in E. coli for conjugate vaccines

finabio.net
Core offering1 text field

Fina Biosolutions develops and supplies proprietary CDAP conjugation chemistry and E. coli-expressed carrier proteins (EcoCRM/CRM197, 8MTT, rTTHc, Qβ VLP) along with functionalized dextrans and specialty immunoreagents for conjugate vaccine manufacturers, particularly emerging market producers. The company complements its product catalog with contract bioconjugation services, protein expression and purification, SEC-MALS and moisture analytical services, CDAP conjugation training programs, and technology licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CRM197 production cost reduced by up to 80% compared to prior commercial options
+3 more records
Product overview1 text field

Fina Biosolutions is a biotech company providing conjugate vaccine laboratory and consulting services along with a portfolio of bioconjugation products. The product portfolio centers on carrier proteins for conjugate vaccines (EcoCRM/CRM197, Tetanus Toxoid/8MTT, rTTHc, Qβ VLP) and functionalized dextrans for research applications. The company offers conjugation services using proprietary CDAP chemistry, protein expression and purification services, analytical services (SEC-MALS, moisture analysis), and CDAP conjugation training programs. All products and services are designed to support vaccine development with a focus on affordability for emerging markets.

Product and service13 records
1EcoCRM (CRM197) Carrier Protein Family
CategoryVaccine Carrier Proteins
Description

E. coli-expressed CRM197 carrier protein and its functionalized variants (maleimide, azide, bromoacetate, click-chemistry) for conjugate vaccine manufacturing and bioconjugation, with anti-CRM antibodies for detection. CRM197 is a genetically detoxified diphtheria toxin used as a carrier protein in conjugate vaccines against pneumococcal, meningococcal, and Haemophilus influenzae b diseases. Available for preclinical research and clinical (cGMP) use.

2Tetanus Toxoid (8MTT) Carrier Protein Family
CategoryVaccine Carrier Proteins
Description

Genetically detoxified tetanus toxin carrier protein and its functionalized variants (maleimide, azide, bromoacetate) for conjugate vaccine development. Used as an alternative carrier protein to CRM197 in conjugate vaccine formulations.

3rTTHc Carrier Protein Family
CategoryVaccine Carrier Proteins
Description

Recombinant tetanus toxin heavy chain fragment C and its maleimide-functionalized variant, used as a genetically detoxified alternative to chemically-treated tetanus toxoid in conjugate vaccine research.

4Qβ VLP
CategoryVaccine Carrier Proteins
Description

Q-beta virus-like particle for vaccine antigen display and delivery applications.

5Functionalized Dextrans
CategoryBioconjugation Reagents
Description

Functionalized dextrans (>90% dextran by weight) including amino, carboxy, amino-ficoll, fluorescent, monofunctionalized, multi-functionalized, and high-ratio maleimide variants for bioconjugation, immunoassay, imaging, tracing, and flow cytometry applications.

6Antibody Dextran Conjugates
CategoryBioconjugation Reagents
Description

Multivalent antibody-dextran conjugates including anti-IgD and anti-IgM constructs used as universal B cell activators in immunology research.

7Streptavidin and Streptavidin Conjugates
CategoryBioconjugation Reagents
Description

Recombinant E. coli-produced streptavidin with high biotin-binding affinity, plus streptavidin-dextran conjugates and fluorescent (PE/APC) streptavidin-dextran conjugates for multivalent binding, flow cytometry, and T-cell analysis applications.

8Specialty Immunoreagents
CategoryBioconjugation Reagents
Description

Collection of immunological reagents including TNP, NP, DNP, phosphorylcholine, phenylarsonate, and heparin conjugates for immunological research.

9Conjugation Services
CategoryLaboratory Services
Description

Contract conjugation services for conjugate vaccines, biotinylation, fluorescent labeling, antibody-enzyme conjugates, and peptide immunogens using proprietary CDAP chemistry. Provided to vaccine developers and biotech companies worldwide.

10CDAP Conjugation Training Program
CategoryTraining and Consulting
Description

Multi-day hands-on training program on CDAP conjugation chemistry taught by founder Dr. Andrew Lees, covering theoretical instruction, laboratory training, Design of Experiment-based optimization, and SEC-MALS analysis. Delivered to scientists from vaccine manufacturers and research institutions.

11Protein Expression and Purification Services
CategoryLaboratory Services
Description

Recombinant protein production services from milligrams to multi-gram quantities using bacterial (E. coli) expression systems. Includes expression, purification, and analytical characterization.

12Analytical Services (SEC-MALS and Moisture Analysis)
CategoryLaboratory Services
Description

Analytical services including size-exclusion chromatography with multi-angle laser light scattering (SEC-MALS) for absolute molecular weight determination of proteins, conjugates, and polymers, plus chemical-free moisture analysis using Vapor Pro technology for polysaccharides and proteins.

13Immunoassay Design and Antibody Services
CategoryConsulting Services
Description

Immunoassay development services and antibody products provided to FinaBio's customers through partner company AIC Biotech.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-07-27
Description

Fina Biosolutions selected Scorpius BioManufacturing, a biologics CDMO, for production of E.coli-expressed CRM197 conjugate vaccine carrier protein. The partnership includes recovery and downstream process optimization, analytical method implementation, validation, scale-up, and cGMP bulk drug substance manufacturing.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2022-10-10
Description

Bio-Works Technologies interviewed Andrew Lees for their Water Cooler Chats video series at BPI Boston 2022, promoting FinaBios' technology and expertise in the bioprocessing community.

3Chinese Institute of Medical Biology (Kunming)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-09-17
Description

Fina Biosolutions signed a development agreement for two conjugate vaccines with the Chinese Institute of Medical Biology (Kunming), part of the Chinese Academy of Medicine. FinaBio provides laboratory and consulting services, develops production protocols, trains scientists, and assists in manufacturing scale-up for bacterial meningitis vaccines.

finabio.net
4PATH
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-11-15
Description

PATH provides funding and technical support for clinical manufacture of EcoCRM (CRM197). FinaBio licensed PATH non-exclusive rights to EcoCRM for infectious disease vaccines sold to low-income countries. PATH supports bringing EcoCRM to GMP manufacture for use in GAVI countries.

finabio.net
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2007-01-01
Description

Licensed CDAP conjugation chemistry under a 2007 technology agreement for pneumococcal conjugate vaccine (Pneumosil) and meningococcal conjugate vaccine (MenFive). FinaBio receives milestone payments and royalties based on worldwide sales. Pneumosil achieved WHO prequalification; MenFive is also WHO prequalified.

6Chengdu Institute of Biological Products
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed conjugation technology from Fina Biosolutions for conjugate vaccine development.

finabio.net
7Canadian Glycomics Network (GlycoNet)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Andrew Lees presented on EcoCRM and carrier proteins to GlycoNet in April 2020. GlycoNet is a Canadian network of glycomics researchers funded by the Networks of Centres of Excellence program.

finabio.net
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global biologics CDMO with extensive microbial expression and conjugation capabilities serving vaccine and therapeutic developers. Comparable as a broad incumbent in the contract biologics manufacturing space that competes for the same customer base.

2MilliporeSigma (Merck KGaA Life Science)
TypeBroad incumbent
Description

Sells CRM197 carrier protein and broad bioconjugation reagents to vaccine developers and researchers — historically the dominant supplier that FinaBio's EcoCRM undercuts by up to 80%. Comparable as an established incumbent in the same carrier protein and bioconjugation market.

TypeDirect peer
Description

US-based biologics CDMO that is FinaBio's selected partner for cGMP production of EcoCRM (CRM197). Directly comparable as a biologics manufacturing services provider, with overlapping capabilities in protein expression, purification, and analytical characterization.

TypeBroad incumbent
Description

One of the world's largest biologics CDMOs, offering microbial and mammalian protein expression, conjugation, and analytical services. Comparable as a broad incumbent providing biologics manufacturing services to vaccine developers globally.

TypeBroad incumbent
Description

Life sciences tools giant offering bioconjugation reagents, protein expression systems, and analytical services. Comparable as a broad incumbent serving vaccine developers and academic researchers with overlapping reagent and service categories.

TypeBroad incumbent
Description

Life sciences tools and reagents company serving vaccine development and immunology research. Comparable as a broad incumbent in the bioconjugation and protein characterization reagent space with similar downstream customer segments.

TypeDirect peer
Description

World's largest vaccine manufacturer by volume and FinaBio's flagship licensing partner for Pneumosil and MenFive. Comparable as an emerging-market conjugate vaccine developer using FinaBio's CDAP chemistry and EcoCRM technology.

TypeDirect peer
Description

Indian vaccine manufacturer and licensor of 8MTT (genetically detoxified tetanus toxin) to FinaBio. Comparable as an emerging-market vaccine manufacturer focused on affordable conjugate vaccines and adjacent biologics.

TypeDirect peer
Description

Indian vaccine manufacturer developing affordable conjugate vaccines for emerging markets. Comparable as a direct peer in the same customer segment (emerging-market vaccine manufacturers) and competes for similar global health tenders.

TypeBroad incumbent
Description

Global biologics CDMO providing protein expression, conjugation, and fill-finish services to vaccine and therapeutic developers. Comparable as a broad incumbent in biologics contract manufacturing with overlapping protein production capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fina Biosolutions

Conjugate Vaccine Technologyfinabio.net

Fina Biosolutions is a Rockville, Maryland biotech that licenses proprietary CDAP conjugation chemistry and E. coli-produced CRM197 (EcoCRM) carrier proteins to enable affordable conjugate vaccine manufacturing, serving emerging market vaccine producers, global health organizations, and research institutions worldwide.

What Fina Biosolutions does

Fina Biosolutions LLC is a privately held biotechnology company founded in 2006 by Dr. Andrew Lees and headquartered in Rockville, Maryland. The company's mission is to enable affordable conjugate vaccine manufacturing for emerging markets by providing conjugation chemistry expertise, carrier proteins, laboratory services, and consulting. Its core technology is the CDAP (1-cyano-4-dimethylaminopyridine tetrafluoroborate) conjugation method and a proprietary E. coli expression system that produces CRM197 (marketed as EcoCRM) at high yields without Corynebacterium diphtheriae, reducing carrier protein costs by up to 80% versus legacy alternatives. The broader product portfolio includes tetanus toxoid variants (8MTT, rTTHc), Qβ virus-like particles, and a catalog of functionalized dextrans for research applications.

Fina Biosolutions operates four revenue streams. First, product sales of proprietary carrier proteins and bioconjugation reagents via a direct e-commerce storefront and purchase-order system, with unit prices ranging from $175 to $5,500. Second, contract laboratory services covering bioconjugation, protein expression and purification, SEC-MALS and moisture analytical services, and immunoassay design. Third, technology licensing and royalties, most notably the long-running agreement with the Serum Institute of India covering CDAP chemistry and EcoCRM, which underlies WHO-prequalified vaccines Pneumosil and MenFive, plus a non-exclusive PATH license for EcoCRM in GAVI-eligible countries. Fourth, multi-day CDAP conjugation training programs delivered by Andrew Lees and staff. The company employs 1-10 people, was bootstrapped for 18 years prior to a $3 million strategic investment by SK Bioscience in October 2024, and operates a deliberately low-margin 'not-for-much profit' model intended to expand global vaccine access rather than maximize unit economics.

Fina Biosolutions firmographics

Firmographics
Name
Fina Biosolutions
Legal name
Fina Biosolutions LLC
Website
https://finabio.net
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Fina Biosolutions is a Rockville, Maryland biotech that licenses proprietary CDAP conjugation chemistry and E. coli-produced CRM197 (EcoCRM) carrier proteins to enable affordable conjugate vaccine manufacturing, serving emerging market vaccine producers, global health organizations, and research institutions worldwide.
Ownership category
akta.pro rank

Fina Biosolutions industry classification

Industry
Product category
Conjugate Vaccine Technology
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Conjugate vaccine technology
  • Bioconjugation services
  • Vaccine carrier proteins
  • Protein expression services
  • Conjugation chemistry

Where Fina Biosolutions is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Fina Biosolutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Product Sales (Carrier Proteins & Reagents): Sale of proprietary vaccine carrier proteins (EcoCRM, rTTHc, 8MTT), functionalized dextrans, specialty immunoreagents, and related bioconjugation reagents to vaccine manufacturers and research institutions. Products sold via online storefront and purchase orders.
  2. Laboratory & Consulting Services: Provides bioconjugation laboratory services, protein expression and purification, analytical services (SEC-MALS, moisture analysis), and consulting to biotech and vaccine companies. Includes contract conjugation work for companies worldwide.
  3. Technology Licensing & Royalties: Licenses CDAP conjugation chemistry and EcoCRM production technology to vaccine manufacturers. Receives milestone payments and royalties on vaccine sales incorporating FinaBio technology (e.g., Serum Institute of India's Pneumosil and MenFive).
  4. CDAP Training Programs: Multi-day training programs on CDAP conjugation chemistry, delivered by Andrew Lees and FinaBio staff, covering theoretical and hands-on laboratory training, DOE-based optimization, and SEC MALS analysis.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goEcoCRM (CRM197) carrier protein
Unit PricingPay-as-you-goAmino Dextrans
Unit PricingPay-as-you-go8MTT (Tetanus Toxoid)
Unit PricingPay-as-you-gorTTHc carrier protein
Unit PricingPay-as-you-goAnti-IgD/IgM Dextran Conjugates
Unit PricingPay-as-you-goQβ VLP
Unit PricingPay-as-you-goSpecialty Immunoreagents (TNP, DNP, NP, etc.)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Fina Biosolutions product offering

Product offering

Core offering

Fina Biosolutions develops and supplies proprietary CDAP conjugation chemistry and E. coli-expressed carrier proteins (EcoCRM/CRM197, 8MTT, rTTHc, Qβ VLP) along with functionalized dextrans and specialty immunoreagents for conjugate vaccine manufacturers, particularly emerging market producers. The company complements its product catalog with contract bioconjugation services, protein expression and purification, SEC-MALS and moisture analytical services, CDAP conjugation training programs, and technology licensing.

Product overview

Fina Biosolutions is a biotech company providing conjugate vaccine laboratory and consulting services along with a portfolio of bioconjugation products. The product portfolio centers on carrier proteins for conjugate vaccines (EcoCRM/CRM197, Tetanus Toxoid/8MTT, rTTHc, Qβ VLP) and functionalized dextrans for research applications. The company offers conjugation services using proprietary CDAP chemistry, protein expression and purification services, analytical services (SEC-MALS, moisture analysis), and CDAP conjugation training programs. All products and services are designed to support vaccine development with a focus on affordability for emerging markets.

Differentiator

Problem solved

Functional benefit

Brands

  • EcoCRM: Economical CRM197 carrier protein produced in E. coli for conjugate vaccines

Products and services

  • EcoCRM (CRM197) Carrier Protein Family E. coli-expressed CRM197 carrier protein and its functionalized variants (maleimide, azide, bromoacetate, click-chemistry) for conjugate vaccine manufacturing and bioconjugation, with anti-CRM antibodies for detection. CRM197 is a genetically detoxified diphtheria toxin used as a carrier protein in conjugate vaccines against pneumococcal, meningococcal, and Haemophilus influenzae b diseases. Available for preclinical research and clinical (cGMP) use.
  • Tetanus Toxoid (8MTT) Carrier Protein Family Genetically detoxified tetanus toxin carrier protein and its functionalized variants (maleimide, azide, bromoacetate) for conjugate vaccine development. Used as an alternative carrier protein to CRM197 in conjugate vaccine formulations.
  • rTTHc Carrier Protein Family Recombinant tetanus toxin heavy chain fragment C and its maleimide-functionalized variant, used as a genetically detoxified alternative to chemically-treated tetanus toxoid in conjugate vaccine research.
  • Qβ VLP Q-beta virus-like particle for vaccine antigen display and delivery applications.
  • Functionalized Dextrans Functionalized dextrans (>90% dextran by weight) including amino, carboxy, amino-ficoll, fluorescent, monofunctionalized, multi-functionalized, and high-ratio maleimide variants for bioconjugation, immunoassay, imaging, tracing, and flow cytometry applications.
  • Antibody Dextran Conjugates Multivalent antibody-dextran conjugates including anti-IgD and anti-IgM constructs used as universal B cell activators in immunology research.
  • Streptavidin and Streptavidin Conjugates Recombinant E. coli-produced streptavidin with high biotin-binding affinity, plus streptavidin-dextran conjugates and fluorescent (PE/APC) streptavidin-dextran conjugates for multivalent binding, flow cytometry, and T-cell analysis applications.
  • Specialty Immunoreagents Collection of immunological reagents including TNP, NP, DNP, phosphorylcholine, phenylarsonate, and heparin conjugates for immunological research.
  • Conjugation Services Contract conjugation services for conjugate vaccines, biotinylation, fluorescent labeling, antibody-enzyme conjugates, and peptide immunogens using proprietary CDAP chemistry. Provided to vaccine developers and biotech companies worldwide.
  • CDAP Conjugation Training Program Multi-day hands-on training program on CDAP conjugation chemistry taught by founder Dr. Andrew Lees, covering theoretical instruction, laboratory training, Design of Experiment-based optimization, and SEC-MALS analysis. Delivered to scientists from vaccine manufacturers and research institutions.
  • Protein Expression and Purification Services Recombinant protein production services from milligrams to multi-gram quantities using bacterial (E. coli) expression systems. Includes expression, purification, and analytical characterization.
  • Analytical Services (SEC-MALS and Moisture Analysis) Analytical services including size-exclusion chromatography with multi-angle laser light scattering (SEC-MALS) for absolute molecular weight determination of proteins, conjugates, and polymers, plus chemical-free moisture analysis using Vapor Pro technology for polysaccharides and proteins.
  • Immunoassay Design and Antibody Services Immunoassay development services and antibody products provided to FinaBio's customers through partner company AIC Biotech.

Quantifiable outcome

  • CRM197 production cost reduced by up to 80% compared to prior commercial options
  • +3 more outcomes

Companies that use Fina Biosolutions

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Fina Biosolutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Fina Biosolutions partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, minor and flagship.

  • Scorpius BioManufacturingcoreImplementation/ SI/ Consulting Partner · 27 July 2023Fina Biosolutions selected Scorpius BioManufacturing, a biologics CDMO, for production of E.coli-expressed CRM197 conjugate vaccine carrier protein. The partnership includes recovery and downstream process optimization, analytical method implementation, validation, scale-up, and cGMP bulk drug substance manufacturing.
  • Bio-Works TechnologiesminorGTM or Marketing Partner · 10 October 2022Bio-Works Technologies interviewed Andrew Lees for their Water Cooler Chats video series at BPI Boston 2022, promoting FinaBios' technology and expertise in the bioprocessing community.
  • Chinese Institute of Medical Biology (Kunming)minorStrategic or Co-development Partner · 17 September 2019Fina Biosolutions signed a development agreement for two conjugate vaccines with the Chinese Institute of Medical Biology (Kunming), part of the Chinese Academy of Medicine. FinaBio provides laboratory and consulting services, develops production protocols, trains scientists, and assists in manufacturing scale-up for bacterial meningitis vaccines.
  • PATHflagshipStrategic or Co-development Partner · 15 November 2018PATH provides funding and technical support for clinical manufacture of EcoCRM (CRM197). FinaBio licensed PATH non-exclusive rights to EcoCRM for infectious disease vaccines sold to low-income countries. PATH supports bringing EcoCRM to GMP manufacture for use in GAVI countries.
  • Serum Institute of IndiaflagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2007Licensed CDAP conjugation chemistry under a 2007 technology agreement for pneumococcal conjugate vaccine (Pneumosil) and meningococcal conjugate vaccine (MenFive). FinaBio receives milestone payments and royalties based on worldwide sales. Pneumosil achieved WHO prequalification; MenFive is also WHO prequalified.
  • Chengdu Institute of Biological ProductsminorOEM/ Whitelabel/ Licensing PartnerLicensed conjugation technology from Fina Biosolutions for conjugate vaccine development.
  • Canadian Glycomics Network (GlycoNet)minorStrategic or Co-development PartnerAndrew Lees presented on EcoCRM and carrier proteins to GlycoNet in April 2020. GlycoNet is a Canadian network of glycomics researchers funded by the Networks of Centres of Excellence program.

Scale indicators8 records

Recent moves11 records

Expansion highlights5 records

Fina Biosolutions competitors and assessment

Company assessment

Broad incumbents

  • WuXi Biologics: Global biologics CDMO with extensive microbial expression and conjugation capabilities serving vaccine and therapeutic developers. Comparable as a broad incumbent in the contract biologics manufacturing space that competes for the same customer base.
  • MilliporeSigma (Merck KGaA Life Science): Sells CRM197 carrier protein and broad bioconjugation reagents to vaccine developers and researchers — historically the dominant supplier that FinaBio's EcoCRM undercuts by up to 80%. Comparable as an established incumbent in the same carrier protein and bioconjugation market.
  • Lonza Group: One of the world's largest biologics CDMOs, offering microbial and mammalian protein expression, conjugation, and analytical services. Comparable as a broad incumbent providing biologics manufacturing services to vaccine developers globally.
  • Thermo Fisher Scientific: Life sciences tools giant offering bioconjugation reagents, protein expression systems, and analytical services. Comparable as a broad incumbent serving vaccine developers and academic researchers with overlapping reagent and service categories.
  • Bio-Rad Laboratories: Life sciences tools and reagents company serving vaccine development and immunology research. Comparable as a broad incumbent in the bioconjugation and protein characterization reagent space with similar downstream customer segments.
  • Catalent (Novo Holdings): Global biologics CDMO providing protein expression, conjugation, and fill-finish services to vaccine and therapeutic developers. Comparable as a broad incumbent in biologics contract manufacturing with overlapping protein production capabilities.

Direct peers

  • Scorpius BioManufacturing: US-based biologics CDMO that is FinaBio's selected partner for cGMP production of EcoCRM (CRM197). Directly comparable as a biologics manufacturing services provider, with overlapping capabilities in protein expression, purification, and analytical characterization.
  • Serum Institute of India: World's largest vaccine manufacturer by volume and FinaBio's flagship licensing partner for Pneumosil and MenFive. Comparable as an emerging-market conjugate vaccine developer using FinaBio's CDAP chemistry and EcoCRM technology.
  • Bharat Biotech: Indian vaccine manufacturer and licensor of 8MTT (genetically detoxified tetanus toxin) to FinaBio. Comparable as an emerging-market vaccine manufacturer focused on affordable conjugate vaccines and adjacent biologics.
  • Biological E Limited: Indian vaccine manufacturer developing affordable conjugate vaccines for emerging markets. Comparable as a direct peer in the same customer segment (emerging-market vaccine manufacturers) and competes for similar global health tenders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Fina Biosolutions social profiles

Digital presence

Fina Biosolutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fina Biosolutions leadership team

Management profile

Number of profiles

Profiles2 records

Fina Biosolutions funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fina Biosolutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fina Biosolutions

What does Fina Biosolutions do?

Fina Biosolutions develops and supplies proprietary CDAP conjugation chemistry and E. coli-expressed carrier proteins (EcoCRM/CRM197, 8MTT, rTTHc, Qβ VLP) along with functionalized dextrans and specialty immunoreagents for conjugate vaccine manufacturers, particularly emerging market producers. The company complements its product catalog with contract bioconjugation services, protein expression and purification, SEC-MALS and moisture analytical services, CDAP conjugation training programs, and technology licensing.

Is Fina Biosolutions a public or private company?

Fina Biosolutions is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Fina Biosolutions founded?

Fina Biosolutions was founded in 2006. It employs 11 to 50 people.

Where is Fina Biosolutions based?

Fina Biosolutions is headquartered in Rockville, United States, in the North America region.

How does Fina Biosolutions make money?

Four revenue lines are on record. Product Sales (Carrier Proteins & Reagents) is the primary driver. The others are laboratory & Consulting Services, technology Licensing & Royalties and CDAP Training Programs.

Who are Fina Biosolutions's main competitors?

Broad incumbents on record are WuXi Biologics, MilliporeSigma (Merck KGaA Life Science), Lonza Group, Thermo Fisher Scientific, Bio-Rad Laboratories and Catalent (Novo Holdings). Direct peers are Scorpius BioManufacturing, Serum Institute of India, Bharat Biotech and Biological E Limited.

Does Fina Biosolutions have an API?

No public API is recorded for Fina Biosolutions.

What industry is Fina Biosolutions in?

Fina Biosolutions's product category is Conjugate Vaccine Technology. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Korea Joongang DailySK bioscience to invest $3 million to Fina BiosolutionsSK bioscience will invest $3 million in Maryland-based conjugate vaccine developer Fina Biosolutions, becoming its first and sole strategic investor. The deal includes FinaBio's technology for Cross-Reacting Material 197 and next-generation conjugation technology. SK bioscience CEO Ahn Jae-yong said the collaboration will advance vaccine development and strengthen global competitiveness.The Manila TimesKorea's SK bioscience Acquires Stake in U.S. Biotech Fina BiosolutionsSK bioscience invested $3 million in U.S. biotech Fina Biosolutions, becoming its sole strategic investor. The investment aims to improve conjugate vaccine immunogenicity and productivity, particularly for pneumococcal and typhoid vaccines. SK bioscience plans to leverage FinaBio's CRM197 technology to advance its vaccine portfolio.PR NewswireKorea's SK bioscience Acquires Stake in U.S. Biotech Fina BiosolutionsSK bioscience invested $3 million in Fina Biosolutions, a U.S. biotech firm developing conjugate vaccines. The investment makes SK bioscience FinaBio's first and sole strategic investor, aiming to improve vaccine immunogenicity and productivity. SK bioscience plans to leverage FinaBio's CRM 197 technology for its own vaccine development.PR NewswireFina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197Fina Biosolutions selected Scorpius BioManufacturing to produce its EcoCRM® CRM197 conjugate vaccine carrier protein. The partnership covers recovery, downstream optimization, analytical methods, validation, scale-up, and cGMP bulk manufacturing. Both companies expressed commitment to a long-term manufacturing partnership.